CONTACT
+91 80 2808 2808
info@biocon.com

News - Posts

Biocon  /  News – Posts

Biocon Academy Achieves 100% Placement within 2.5 hours for Quality Control Analytical Program

  • Posted by: BIOCON

USFDA Classifies Biocon Biologics’ Biocon Park Site in Bengaluru, India as Voluntary Action Initiated (VAI)

  • Posted by: BIOCON

Biocon Q2FY25 Revenue at Rs 3,623 Cr, EBITDA at Rs 718 Cr

  • Posted by: BIOCON

Biocon Biologics’ Drug Substance Facility in Bengaluru Classified as Voluntary Action Indicated (VAI)

  • Posted by: BIOCON

Biocon Continues to be Among Science Magazine’s Top 10 Global Employers List

  • Posted by: BIOCON

Biocon Foundation Honored with ‘Doing Good for Bharat Awards 2024’ in ‘Healthcare Category’ for ‘eLAJ Smart Clinics’ by the CSR Box

  • Posted by: BIOCON

Biocon Biologics Announces Results of Aflibercept Switching Study at American Academy of Ophthalmology Annual Meeting

  • Posted by: BIOCON

Biocon Biologics’ Commissioned Report Highlights Pathways to Increase Adoption of Biosimilars in LMICs

  • Posted by: BIOCON

Biocon Biologics Refinances USD 1.1 Billion (INR 93,468 million) Long Term Debt through USD Bonds and New Syndicated Facility

  • Posted by: BIOCON

US FDA Completes Inspection at Biocon Biologics’ Insulins Facility at Johor Bahru, Malaysia

  • Posted by: BIOCON
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>